Infant Bacterial Therapeutics

Executive Summary

Infant Bacterial Therapeutics (IBT) is a Swedish biopharmaceutical company focused on developing microbiome-based therapies for infants, particularly premature infants. Its lead candidate, IBP-9414, is a formulated bacterial strain naturally found in breast milk, designed to prevent necrotizing enterocolitis (NEC) and other complications in preterm neonates. The company has completed Phase 2 clinical trials demonstrating safety and efficacy signals, positioning IBP-9414 as a potential first-in-class treatment for a devastating condition with no approved therapies. IBT is currently preparing for Phase 3 trials, which, if successful, could address a significant unmet medical need and drive substantial value. The company operates in the high-growth microbiome therapeutics space and has attracted attention from investors and partners due to its focused pipeline and strong scientific foundation. With a lean operational structure and clear regulatory pathway in both the US and EU, IBT represents a compelling opportunity in pediatric rare disease therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 3 trial for IBP-941485% success
• H2 2027Interim efficacy data from ongoing Phase 2/3 study60% success